Clinical trials: Influenza Human
Healthy or Stable Underlying Chronic Medical Condition
A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age
The objective of this study was to show that quadrivalent live attenuated influenza vaccine (Q/LAIV; MEDI3250) produced antibody levels similar to those produced by the commercial vaccine, FluMist.
- Trial name
- MI-CP185 (NCT00860067)
- Testing
- Q/LAIV (MEDI3250), FluMist/B/Yamagata, FluMist/B/Victoria
- Where
- 18 sites in United States
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults
This trial will assess the immunogenicity and safety of GSK Biologicals' vaccine GSK1557484A, prepared from old concentrated monobulk material, in adults aged 18 to 64 years, when administered up to 5 years following production.
- Trial name
- NCT01416571
- Testing
- Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Interpandemic Influenza
Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009
Trial for annual approval of interpandemic influenza vaccines
- Trial name
- NCT00734734
- Testing
- Seasonal Influenza Vaccine
- Where
- 2 sites in Italy
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Birth Outcomes, Safety
Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study
This study is a prospective, randomized clinical trial. During this study, pregnant women will be randomly assigned to receive IIV and mRNA COVID-19 vaccine either simultaneously or sequentially (7-14 days apart).
- Conditions
- Birth Outcomes, Safety, Adverse Event Following Immunization
- Trial name
- NCT06503900
- Testing
- mRNA COVID-19 vaccine, IIV4 (quadrivalent inactivated influenza vaccine)
- Where
- 6 sites in United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Duke University
Influenza, Behavior and Behavior Mechanisms
Nationwide Utilization of Danish Government Electronic Letter System for Increasing InFLUenza Vaccine Uptake
In randomized clinical trials and observational studies, influenza vaccination has been shown to be effective in reducing influenza-related illness, hospitalizations, cardiovascular events, and mortality in select populations.
- Trial name
- NUDGE-FLU (NCT05542004)
- Testing
- Behavioral Economic Principles
- Where
- Denmark
- Volunteers
- 964,870 people, healthy volunteers welcome
- Sponsor
- Tor Biering-Sørensen
SARS-CoV-2, Influenza
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old
The primary goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1073 compared to co-administered mRNA-1010 and mRNA-1273 vaccines and to the individual vaccines alone in healthy participants.
- Trial name
- NCT05375838
- Testing
- mRNA-1073, mRNA-1010, mRNA-1273
- Where
- 14 sites in United States
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza
Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years
This study will evaluate the safety and immunogenicity of VAX161B [STF2.HA5 H5N1], a recombinant, inactivated, subunit influenza vaccine given as a two dose regimen at a range of doses.
- Trial name
- NCT01560793
- Testing
- VAX161 [STF2.HA5 H5N1]
- Where
- 2 sites in United States
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- VaxInnate Corporation
Newborn Morbidity
Impact of Explanation Given to Parents on Rate of Post-partum Influenza Vaccination
The aim of this study is to determine whether an explanation to parents for the need for post-partum influenza vaccination will influence their compliance.
- Trial name
- NCT03053674
- Testing
- Oral and written explanation, Follow-up questionnaire
- Where
- Israel
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Hillel Yaffe Medical Center
Influenza
Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age
The purpose of this study is to assess the immunogenicity and safety of GSK Biologicals' quadrivalent influenza vaccine (GSK2282512A) compared to Sanofi Pasteur's Fluzone® Quadrivalent in children 6 to 35 months of age.
- Trial name
- NCT02242643
- Testing
- FluLaval™ Quadrivalent, Fluzone® Quadrivalent
- Where
- 66 sites in United States, Mexico
- Volunteers
- 2,432 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Children's Distress During Flu Vaccination
Reducing Children's Distress Towards Flu Vaccinations
Millions of children in North America receive an annual flu vaccination, many of whom are at risk of experiencing severe distress. Children frequently use technologically advanced devices such as computers and cell phones.
- Trial name
- NCT01529021
- Where
- Canada
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- University of Calgary
Influenza
T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009
This study will compare influenza vaccine responses in monozygotic and dizygotic twins.
- Trial name
- NCT01987349
- Testing
- Fluzone® (intramuscular), FluMist® (intranasal)
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Stanford University
Influenza
Safety and Immunogenicity of Co-administration of Candidate Influenza Vaccine MVA-NP+M1 and Viroflu® Seasonal Influenza Vaccine
This is a single blinded placebo controlled phase I study, to assess the safety and immunogenicity of co-administration of the candidate influenza vaccine MVA-NP+M1 with the Viroflu® seasonal influenza vaccine.
- Trial name
- NCT02014168
- Testing
- Viroflu® and MVA-NP+M1
- Where
- United Kingdom
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Influenza, Avian
Two Doses of GHB04L1 for Pandemic Influenza Prophylaxis in Healthy Adults
This study evaluates safety, tolerability and immunogenicity of two doses of GHB04L1, a liquid formulation of the replication- deficient influenza A/Vietnam/1203/04(H5N1)-like ∆NS1 virus in healthy adults.
- Trial name
- NCT03745274
- Testing
- GHB04L1
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AVIR Green Hills Biotechnology AG
Influenza
Heterosubtypic Immune Responses to Influenza in Older People
Vaccination is the principal means of combating epidemic and pandemic influenza. As vaccines induce relatively strain-specific and short-lived antibody responses, annual immunisation with regularly updated vaccine is recommended…
- Trial name
- NCT00798343
- Testing
- Seasonal vaccine, H5 vaccine
- Where
- United Kingdom
- Volunteers
- 292 people, healthy volunteers welcome
- Sponsor
- University Hospitals, Leicester
Influenza
Safety, Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)
This trial is designed to assess the safety and immunogenicity of a prime-boost schedule of GSK Biologicals' investigational vaccine GSK2340272A in children aged between 6 and 35 months.
- Trial name
- NCT00971321
- Testing
- Pandemic influenza vaccine GSK2340272A
- Where
- 5 sites in Spain
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Virus Diseases
Group Study of the Safety of and Immune Response to a Single Dose of Bird Flu Vaccine (H7N3) in Healthy Adults
Over the past decade, avian influenza (AI) has become a major health concern. The development of safe and effective vaccines against avian strains that infect people is important.
- Trial name
- NCT00853255
- Testing
- Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Novel 2009 Influenza H1N1, Influenza, Human
Tolerability and Immunogenicity Study of FLUVAL P H1N1 Flu Vaccine of Omninvest in Children and Adolescents
This is a single-blind, reference drug controlled study to assess safety and tolerability of FLUVAL P H1N1 monovalent influenza vaccine (whole virus, inactivated, adjuvanted with alumn phosphate gel) containing 6 mcgHA per 0.5mL…
- Trial name
- NCT01407978
- Testing
- Vaccination with Fluval P monovalent influenza vaccine, Vaccination with Fluval AB, Vaccination with Fluval AB Novo
- Where
- Hungary
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Influenza Virus Infection, Trained Immunity
Effects of BCG on Influenza Induced Immune Response
In the present study, the investigators want to investigate whether prior BCG-vaccination improves the efficacy of influenza ("the flu") vaccination in young and/or old healthy volunteers and consequently could protect against…
- Trial name
- NCT02114255
- Testing
- BCG
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Immunization, Human Influenza
Study of Yili Mei Yi Tian Active Lactobacillus Drink to Improve Immunity and Digestive System
Study on Evaluating the Promote Effect of Yili Mei Yi Tian Active Lactobacillus Drink on Immunity and Physical Intestinal Canal
- Conditions
- Immunization, Human Influenza, Common Cold, Constipation
- Trial name
- NCT01677715
- Testing
- Yili "Mei Yi Tian" active lactobacillus drink, recombined milk drink contains no lactobacillus
- Where
- 2 sites in China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Inner Mongolia Yili Industrial Group Co., Ltd
Influenza A
A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)
The purpose of this study is to evaluate the safety and immunogenicity of two investigational vaccines, AZD4117 and AZD5315 to protect against certain strains of avian Influenza A (H5N1 and H7N9 subtypes).
- Trial name
- PANDA (NCT07128615)
- Testing
- AZD4117, AZD5315
- Where
- 14 sites in United States
- Volunteers
- 405 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.